Morning Overview on MSN

The FDA weighs an Aug. 25 decision on a drug that pushed stomach-cancer survival past two years

Federal drug regulators are weighing a decision, expected around Aug. 25, 2026, on a treatment regimen that pushed median ...
Yahoo

Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer

Akeso's cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in first-line gastric or gastroesophageal cancer. The AK104-302 trial ...
Morningstar%2c Inc.

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term ...
Brattleboro Reformer

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population. In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the ...
Nasdaq

NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to ...
ascopubs.org

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer Fifty-seven patients ...